Measles immunization in Iran

Mass immunization with live measles vaccine has been carried out in rural Iran since 1968. Two strains have been used: primary baby calf kidney cell-adapted Sugiyama strain and human diploid cell-adapted AIK strain. More than 94% of the susceptible children experimentally vaccinated with either of t...

Full description

Saved in:
Bibliographic Details
Published inReviews of infectious diseases Vol. 5; no. 3; p. 491
Main Author Mirchamsy, H
Format Journal Article
LanguageEnglish
Published United States 01.05.1983
Subjects
Clinical Trials as Topic
Humans
Iran
Measles - complications
Measles - prevention & control
Measles Vaccine - administration & dosage
National Health Programs
Rural Population
Subacute Sclerosing Panencephalitis - etiology
Vaccines, Attenuated - administration & dosage
Iran
Online AccessGet more information

Cover

More Information
Summary:Mass immunization with live measles vaccine has been carried out in rural Iran since 1968. Two strains have been used: primary baby calf kidney cell-adapted Sugiyama strain and human diploid cell-adapted AIK strain. More than 94% of the susceptible children experimentally vaccinated with either of the two vaccines have shown seroconversion. Mass immunization in rural regions has covered about 80% of susceptible children. It is now recommended that the live vaccine be administered twice: the first dose at six to nine months and the second at 12-15 months of age. In all of 100 cases of subacute sclerosing panencephalitis (SSPE) observed in the Tehran region between 1977 and 1982, the patient had a history of measles infection in childhood; there was no indication that SSPE developed after vaccination. Most of the patients with SSPE have had a high titer of antibody to measles virus in serum and cerebrospinal fluid, and antibody has commonly been demonstrated in saliva as well.
ISSN:0162-0886